[go: up one dir, main page]

WO2009158431A3 - Composés et compositions en tant qu’inhibiteurs de kinase - Google Patents

Composés et compositions en tant qu’inhibiteurs de kinase Download PDF

Info

Publication number
WO2009158431A3
WO2009158431A3 PCT/US2009/048509 US2009048509W WO2009158431A3 WO 2009158431 A3 WO2009158431 A3 WO 2009158431A3 US 2009048509 W US2009048509 W US 2009048509W WO 2009158431 A3 WO2009158431 A3 WO 2009158431A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidine derivatives
kinase inhibitors
analplastic
igf
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/048509
Other languages
English (en)
Other versions
WO2009158431A2 (fr
Inventor
Thomas H. Marsilje, Iii
Wenshuo Lu
Bei Chen
Xiaohui He
Songchun Jiang
Kunyong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Priority to CN200980129584XA priority Critical patent/CN102203083A/zh
Priority to US13/000,999 priority patent/US8445505B2/en
Priority to JP2011516619A priority patent/JP2011526291A/ja
Priority to EA201100078A priority patent/EA201100078A1/ru
Priority to MX2010014568A priority patent/MX2010014568A/es
Priority to CA2729546A priority patent/CA2729546A1/fr
Priority to EP09770964A priority patent/EP2331526A2/fr
Priority to AU2009262198A priority patent/AU2009262198B2/en
Publication of WO2009158431A2 publication Critical patent/WO2009158431A2/fr
Publication of WO2009158431A3 publication Critical patent/WO2009158431A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de pyrimidine et des compositions pharmaceutiques de ceux-ci, ainsi que des procédés d’utilisation de ces composés. Par exemple, les dérivés de pyrimidine de l’invention peuvent être utilisés pour traiter, améliorer ou prévenir une pathologie sensible à l’inhibition du facteur de croissance insulinomimétique (IGF-1R) ou de la kinase du lymphome anaplasique (ALK).
PCT/US2009/048509 2008-06-25 2009-06-24 Composés et compositions en tant qu’inhibiteurs de kinase Ceased WO2009158431A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN200980129584XA CN102203083A (zh) 2008-06-25 2009-06-24 作为激酶抑制剂的嘧啶衍生物
US13/000,999 US8445505B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors
JP2011516619A JP2011526291A (ja) 2008-06-25 2009-06-24 キナーゼ阻害剤としてのピリミジン誘導体
EA201100078A EA201100078A1 (ru) 2008-06-25 2009-06-24 Производные пиримидина в качестве ингибиторов киназы
MX2010014568A MX2010014568A (es) 2008-06-25 2009-06-24 Derivados de pirmidina como inhibidores de cinasa.
CA2729546A CA2729546A1 (fr) 2008-06-25 2009-06-24 Composes et compositions en tant qu'inhibiteurs de kinase
EP09770964A EP2331526A2 (fr) 2008-06-25 2009-06-24 Dérivés de la pyrimidine comme inhibiteurs de kinases
AU2009262198A AU2009262198B2 (en) 2008-06-25 2009-06-24 Pyrimidine derivatives as kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
US61/075,583 2008-06-25

Publications (2)

Publication Number Publication Date
WO2009158431A2 WO2009158431A2 (fr) 2009-12-30
WO2009158431A3 true WO2009158431A3 (fr) 2010-03-11

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048509 Ceased WO2009158431A2 (fr) 2008-06-25 2009-06-24 Composés et compositions en tant qu’inhibiteurs de kinase

Country Status (11)

Country Link
EP (1) EP2331526A2 (fr)
JP (1) JP2011526291A (fr)
KR (1) KR20110020940A (fr)
CN (1) CN102203083A (fr)
AU (1) AU2009262198B2 (fr)
BR (1) BRPI0914545A2 (fr)
CA (1) CA2729546A1 (fr)
EA (1) EA201100078A1 (fr)
MX (1) MX2010014568A (fr)
UA (1) UA101057C2 (fr)
WO (1) WO2009158431A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (fr) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
CA2850594C (fr) * 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Derives aminopyrimidiniques utilises comme modulateurs de lrrk2
US9206166B2 (en) 2012-11-06 2015-12-08 SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES Certain protein kinase inhibitors
TR201911151T4 (tr) * 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
WO2015180685A1 (fr) * 2014-05-30 2015-12-03 北京浦润奥生物科技有限责任公司 Inhibiteur de la kinase alk, son procédé de préparation et son utilisation
US10377743B2 (en) * 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN107488148A (zh) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 一种苯丙酰胺类杀虫剂及其制备方法
BR112020012635A2 (pt) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
AU2021218739A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Inhibitors of ULK1/2 and methods of using same

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques
WO2003026666A1 (fr) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Derives de 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine utilises comme inhibiteurs de la kinase, en particulier comme inhibiteurs de la kinase src
WO2005016893A2 (fr) * 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs
WO2005026158A1 (fr) * 2003-09-16 2005-03-24 Novartis Ag Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
WO2006074057A2 (fr) * 2004-12-30 2006-07-13 Exelixis, Inc. Modulateurs de kinase et procedes d'utilisation
WO2007027238A2 (fr) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase jak et utilisations de ceux-ci
WO2008005538A2 (fr) * 2006-07-05 2008-01-10 Exelixis, Inc. Procédés d'utilisation de modulateurs de kinase igf1r et abl
US20080176881A1 (en) * 2006-12-08 2008-07-24 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009017838A2 (fr) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009103652A1 (fr) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulateurs de la bêta-amyloïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4741491B2 (ja) * 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
PL2091918T3 (pl) * 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064655A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy) pyrimidines substitues en 5, utilises comme agents antineoplasiques
WO2003026666A1 (fr) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Derives de 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine utilises comme inhibiteurs de la kinase, en particulier comme inhibiteurs de la kinase src
WO2003026664A1 (fr) * 2001-09-26 2003-04-03 Bayer Corporation Derives de la 2-phenylamino-4- (5-pyrazolylamino) -pyramidine, inhibiteurs de kinases et en particulier de la kinase src
WO2005016893A2 (fr) * 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
WO2005026158A1 (fr) * 2003-09-16 2005-03-24 Novartis Ag Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs
WO2006074057A2 (fr) * 2004-12-30 2006-07-13 Exelixis, Inc. Modulateurs de kinase et procedes d'utilisation
WO2007027238A2 (fr) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase jak et utilisations de ceux-ci
WO2008005538A2 (fr) * 2006-07-05 2008-01-10 Exelixis, Inc. Procédés d'utilisation de modulateurs de kinase igf1r et abl
US20080176881A1 (en) * 2006-12-08 2008-07-24 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009017838A2 (fr) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009103652A1 (fr) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulateurs de la bêta-amyloïde

Also Published As

Publication number Publication date
EA201100078A1 (ru) 2011-08-30
AU2009262198B2 (en) 2012-09-27
WO2009158431A2 (fr) 2009-12-30
JP2011526291A (ja) 2011-10-06
KR20110020940A (ko) 2011-03-03
EP2331526A2 (fr) 2011-06-15
CA2729546A1 (fr) 2009-12-30
CN102203083A (zh) 2011-09-28
BRPI0914545A2 (pt) 2017-05-23
UA101057C2 (en) 2013-02-25
AU2009262198A1 (en) 2009-12-30
MX2010014568A (es) 2011-03-29

Similar Documents

Publication Publication Date Title
WO2010002655A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase
WO2009032668A3 (fr) Composés et compositions en tant qu'inhibiteurs de kinase
WO2009158431A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase
WO2008073687A3 (fr) Composés et compositions inhibant la protéine kinase
UA100846C2 (uk) Сполуки та композиція як інгібітори протеїнкінази
WO2009126514A8 (fr) Composés et compositions en tant qu'inhibiteurs de kinase
WO2009126515A8 (fr) Composés et compositions comme inhibiteurs de la protéine kinase
WO2008049123A8 (fr) Compositions et procédés pour l'inhibition de la voie jak
WO2006123113A3 (fr) Composes chimiques
MY148634A (en) Pyridazinone derivatives
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
WO2008076862A3 (fr) Composés organiques
WO2008046919A3 (fr) Composés hétérocycliques et leur utilisation comme inhibiteurs de la glycogène synthase kinase 3
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2009108383A3 (fr) Dérivés de xanthine substitués
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2009094560A3 (fr) Thiénopyranones en tant qu'inhibiteurs de kinase
WO2009121535A3 (fr) Composés antiprolifératifs et leurs utilisations thérapeutiques
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
WO2009156041A3 (fr) Dérivés de thiazolyl-piperidine
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980129584.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770964

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/014568

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 13000999

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2729546

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011516619

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009262198

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009770964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 432/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117001749

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201100078

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2009262198

Country of ref document: AU

Date of ref document: 20090624

Kind code of ref document: A